Day: April 10, 2024

Meðfylgjandi má finna staðfestingu PricewaterhouseCoopers ehf. á skýrslu Íþöku fasteigna ehf. um fjárhagsleg skilyrði í tengslum við skuldabréf í flokkunum ITHAKA 291128, ITHAKA 070627 ITHAKA 051233. Útreikningar og staðfesting fjárhagslegra skilyrða skal fara fram í kjölfar birtingu árs- og árshlutareiknings félagsins, en ársreikningur Íþöku fasteigna ehf. fyrir árið 2023 var birtur þann 27. mars 2024. Yfirferð eftirlitsaðila á fjárhagslegum skilyrðum samræmist mati Íþöku fasteigna ehf. og var skýrsla félagsins um fjárhagsleg skilyrði staðfest. Nánari upplýsingar veitir Gunnar Valur Gíslason, framkvæmdastjóri, í síma 822-4403 eða í tölvupósti á gunnarvalur@ithaka.is.AttachmentStaðfesting eftirlitsaðila vegna skuldabréfaflokka ITHAKA 291128_070627_051233

RUSTON, La., April 10, 2024 (GLOBE NEWSWIRE) — Origin Bancorp, Inc. (NYSE: OBK) (“Origin”), the financial holding company for Origin Bank, plans to issue first quarter 2024 results after the market closes on Wednesday, April 24, 2024, and hold a conference call to discuss such results on Thursday, April 25, 2024, at 8:00 a.m. Central Time (9:00 a.m. Eastern Time). The conference call will be hosted by Drake Mills, Chairman, President and CEO of Origin, William J. Wallace, IV, Chief Financial Officer of Origin, and Lance Hall, President and CEO of Origin Bank. Conference Call and Live Webcast To participate in the live conference call, please dial +1 (929) 272-1574 (U.S. Local / International 1); +1 (857) 999-3259 (U.S. Local / International 2); +1 (800) 528-1066 (U.S. Toll Free), enter Conference ID: 22041 and request to be joined...

Paris, 10 April 2024, 6:00 p.m. PRESS RELEASE Availability of the 2023 Universal Registration Document including the integrated report Eramet announces the filing of its 2023 Universal Registration Document (“URD”) with the French Financial Markets Authority (Autorité des Marchés Financiers, “AMF”) today. The document was submitted in European Single Electronic Format (“ESEF”), as established by Delegated Regulation (EU) 2019/815. The URD is available on the AMF’s website as well as on the Company’s website (www.eramet.com, in the Investors / Regulated Information section). Copies of this document are also available, free of charge, at the Company’s registered office located at: 10, boulevard de Grenelle, 75015 Paris, France. The 2023 URD includes the following documents:2023 annual financial report, including the Statement on...

OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung CancerNantes, France – April 10, 2024 – 6:00 pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the Company has received €8.4 million in non-dilutive funding under the “i-Démo” call for projects as part of the plan “France 2030” operated by Bpifrance on behalf of the State. This plan aims at developing industrial companies in growth markets that create value and competitiveness for the French economy and also contribute to energy, ecological and digital transitions. This financial support applies from the feasibility study to marketing. This public funding will support the registration Phase 3 clinical trial of neoepitope-based cancer vaccine Tedopi®, in second...

ORMOND BEACH, Fla. and GERMANTOWN, Md., April 10, 2024 (GLOBE NEWSWIRE) — Germfree, a leading innovator in modular cleanroom infrastructure and services, and Orgenesis Inc. (Nasdaq: ORGS), a global leader in decentralizing cell and gene therapies (CGTs), today announced an asset purchase and strategic partnership aimed at advancing Orgenesis’ therapeutic programs and its suite of product development and GMP cell processing services. The collaboration’s goal is to transform the production of cell and gene therapies, making these vital treatments more affordable and accessible to patients worldwide. By combining Germfree’s expertise in designing, manufacturing, and maintaining advanced manufacturing facility environments with Orgenesis’ cutting-edge processes and analytical development capabilities, the partnership seeks to significantly...

Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers IND for APR-1051 has been cleared; details on planned Phase 1 first in human trial (ACESOT-1051) presented ATRN-119, a novel macrocyclic ATR inhibitor, continues to appear safe and well tolerated with no Dose Limiting Toxicities observed in ongoing Phase 1/2a study; preliminary signs of clinical benefit reported; enrollment in the study continues DOYLESTOWN, Pa., April 10, 2024 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today released details about four poster presentations at the ongoing American Association...

SPRING CITY, Pa., April 10, 2024 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced its newest community, Riverstone Crossing, is coming soon to East Vincent Township in Chester County, Pennsylvania. Construction of the Toll Brothers Sales Center and model homes, located at 202 Polaris Drive in Spring City, Pennsylvania, is set to begin in the summer of 2024 and sales will start this fall. Located just minutes from Phoenixville and Collegeville, Riverstone Crossing will include 33 Toll Brothers single-family homes in a private location with a beautiful tree-lined backdrop. Home buyers will be able to choose from three exquisite home designs ranging from 2,583 to over 3,029 square feet of luxury living space, each built with the outstanding quality, craftsmanship, and...

Grenoble, April 10, 2024 – 6:00 pm CEST – The Board of Directors of McPhy Energy (the “Company”), meeting on April 9, 2024, decided to submit to the next Combined Shareholders’ Meeting, to be held on May 30, 2024, in its ordinary part, for approval the proposed transfer of the Company’s shares listing from the regulated market of Euronext Paris (compartment C) to the organized multilateral trading facility of Euronext Growth Paris. Reasons for the proposed transfer This proposed transfer would enable the Company to have its shares admitted to trading on a growth market for SMEs, in line with its current size and share profile, and would alleviate the obligations and constraints with which it has currently to comply. This would enable the Company to simplify and reduce the resources mobilized for its listing, while benefiting...